Clinical Trial Update: Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix [Phase 2]

View source ↗

Summary

This entry notes a Phase II study of Cadonilimab (AK104) for recurrent small cell neuroendocrine carcinoma of the cervix. The trial is currently active but not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Small Cell Neuroendocrine Carcinoma of the Cervix

Drugs mentioned

• Cadonilimab (AK104) (Cadonilimab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Carcinomas, Cervix Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING